AstraZeneca shares fell 15 percent after disappointing results for a lung cancer treatment in highly anticipated clinical trial.
Europe's largest oil firm Royal Dutch Shell has beaten analyst expectations, reporting profits for its second quarter that are three times larger than this time last year.
Roche CEO Severin Schwan told CNBC that the company's strategy "has always been and remains to move the standard of care, to bring better medicines."
Roche CEO Severin Schwan discusses the pharmaceutical company's better-than-expected first-half earnings.
CNBC’s Carolin Roth talks about the performance of Roche in light of its recent earnings release, with comment from the company’s CEO Severin Schwan.
CNBC's Carolin Roth discusses first-half earnings; pharmaceuticals company Roche's earnings beat expectations slightly.
Socially responsible funds may not beat traditional equity funds, but SRI funds are generating good enough performance to be worth it.
Roche-backed Foundation Medicine will bring its genomic sequencing of tumors to China in the third quarter.
Jim Cramer explained why he thinks Apple is dominating consumer products, if not tech.
European markets closed lower on Tuesday as investors erred on the side of caution ahead of potentially market-moving events later in the week.
A trial from Roche combining its newer targeted drug for breast cancer with an older treatment showed only a modest benefit for women with a specific type of disease, according to data. CNBC’s Carolin Roth looks at the share price reaction.
CNBC's Meg Tirrell reports the latest findings on Roche's breast cancer drug Perjeta and lung cancer drug Alecensa from the American Society of Clinical Oncology Conference.
CNBC's Meg Tirrell reports on what stocks to watch during ASCO, the biggest cancer research conference in Chicago. The “Fast Money Halftime Report” traders weigh in.
A new technology startup called Genome Medical has a plan to address the shortage of genetic counselors.
ASCO's abstract drop reveals the progress being made in attacking cancer and, inevitably, moves stocks both large and small.
So far this year, markets abroad are leaving U.S. equities in the dust, and some strategists say the outperformance could continue to accelerate.
Health companies have been chasing the problem of non-invasive blood sugar monitoring for decades
CNBC's Meg Tirrell takes a look at how big pharma is responding to President Trump.
Contract manufacturing firm Samsung BioLogics has denied allegations it juggled its accounting practices.
Roche remains committed to the U.S. despite President Donald Trump's pledges to crackdown on pharmaceutical companies "getting away with murder."